Ikarian Capital’s Corvus Pharmaceuticals CRVS Stock Holding History

Ikarian Capital’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-510,126	Closed	-$837K	–	157
2022 Q1	$837K	Buy	510,126 +27,516	+6%	+$50.4K	0.11%	105
2021 Q4	$1.16M	Sell	482,610 -274,935	-36%	-$1.07M	0.17%	94
2021 Q3	$3.67M	Buy	757,545 +657,545	+658%	+$1.95M	0.26%	86
2021 Q2	$267K	Hold	100,000	–	–	0.02%	203
2021 Q1	$307K	Buy	+100,000	New	+$361K	0.01%	265

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ikarian Capital's CRVS Position: Q2 2022 in Review

Ikarian Capital sold out of Corvus Pharmaceuticals (CRVS) in Q2 2022, closing a stake of 510,126 shares — an estimated $837K sold.

Ikarian Capital first reported a position in CRVS in Q1 2021 and held it in 5 quarters. The position peaked at $3.67M in Q3 2021. 47 funds tracked by Wall St. Rank hold CRVS as of Q2 2022.

Ikarian Capital reported no remaining Corvus Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Ikarian Capital sold 510,126 Corvus Pharmaceuticals shares in Q2 2022, an estimated $837K.
Ikarian Capital first reported a position in Corvus Pharmaceuticals in Q1 2021 and held it in 5 quarters.
Ikarian Capital's Corvus Pharmaceuticals position peaked at $3.67M in Q3 2021.
47 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.